302例中重度类风湿关节炎患者接受阿达木单抗治疗后生存质量的调查研究

摘要

Objective:To explore the effect of adalimumab on quality of life (QOL) of patients with moderate to severe rheumatoid arthritis. Methods:A total of 302 patients with rheumatoid arthritis were given adalimumab intervention for 24 weeks. A randomized, double-blind placebo-controlled study was carried out in the ifrst 12 weeks, and the patients were divided into three groups, adalimumab 40 mg group, adalimumab 80 mg group, placebo group. The following 12 weeks was a open study, all the patients received subcutaneous administration of adalimumab 40 mg, once every two weeks. The QOL of each patient before and after intervention was assessed and compared by using SF-36 scale. Results:After intervention, physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health were improved signiifcantly. Conclusion:Adalimumab helps to improve the QOL of patients with rheumatoid arthritis.%目的：观察阿达木单抗治疗对中重度类风湿关节炎患者生存质量的影响。方法：前12周为随机、双盲、安慰剂对照临床研究，后12周为开放研究。302例活动性类风湿关节炎患者接受前12周阿达木单抗40 mg、80 mg或安慰剂的治疗，隔周皮下给药，所有受试者在12~24周接受隔周皮下给药40 mg的阿达木单抗治疗，在干预前和干预后采用SF-36生存质量量表对患者的生存质量进行评定和比较。结果：干预后本组SF-36生存质量量表得分在生理功能、生理职能、躯体疼痛、总体健康、活力、社会功能、情感职能、精神健康8个维度较干预前有明显的提高。结论：阿达木单抗有利于改善类风湿关节炎患者的生存质量。